Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685796 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13973930 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13073574 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13974203 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL91017 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL15002730 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13165209 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL14819870 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL24390382 | 0.98 | GLP1R (0.65) | GLP1RNOD1SELPFOLH1 | |
| SCHEMBL18626065 | 0.98 | GLP1R (0.65) | GLP1RNOD1SELPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737612-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-08-22 | — | — | US | disclosed |
| US-9713644-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-07-25 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-20140294853-A1 | ANTAGONISTIC DR3 LIGANDS | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-8765130-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-20130252884-A1 | FGF21 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-09-26 | — | — | US | disclosed |
| US-8536122-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-09-17 | — | — | US | disclosed |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-20120295847-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2012-11-22 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | GLP1R 45/4885NOD1 1001/4885SELP 166/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1340/4885SELP 1274/4885 |
| US-20120295847-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1340/4885SELP 1274/4885 |
| US-20140294853-A1 | ANTAGONISTIC DR3 LIGANDS | ACKR3, FPR3, FCGR3B | GLP1R 1320/4885NOD1 1619/4885SELP 36/4885 |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1856/4885SELP 1632/4885 |
| US-20130252884-A1 | FGF21 ANALOGUES AND DERIVATIVES | FGFR1, FGF1, FGF23 | GLP1R 12/4885NOD1 812/4885SELP 2609/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | GLP1R 1/4885NOD1 410/4885SELP 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.